Darmstadt, Germany

Wighard Strehlow


Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1978-1980

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Wighard Strehlow: Innovator in Pharmaceutical Chemistry

Introduction

Wighard Strehlow is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of central nervous system depressants. With a total of 4 patents to his name, his work has had a considerable impact on the industry.

Latest Patents

Strehlow's latest patents include innovative compounds such as 3-Fluorobenzodiazepines, specifically 3-Fluoro-2,3-dihydro-1H-1,4-benzodiazepin-2-ones. These compounds are characterized by their formula, wherein R¹ can be hydrogen, alkyl, or fluorinated alkyl of 1-4 carbon atoms, and up to 9 fluorine atoms or cycloalkylalkyl of 4-8 carbon atoms. R² is phenyl, monohalophenyl, or pyridyl, while R³ can be fluorine, chlorine, bromine, or nitro. These compounds are recognized for their potential as central nervous system depressants. Another significant patent involves phenoxy heterocyclic amines, specifically phenoxyalkylamines, which have various applications in medicinal chemistry.

Career Highlights

Throughout his career, Wighard Strehlow has worked with prominent organizations, including Merck Patent Gesellschaft mit beschränkter Haftung. His expertise in pharmaceutical innovations has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

Strehlow has collaborated with notable professionals in the field, including Jurgen Uhl and Dieter Marx. These collaborations have further enhanced his contributions to pharmaceutical research and development.

Conclusion

Wighard Strehlow's work in pharmaceutical chemistry exemplifies innovation and dedication to advancing medical science. His patents and collaborations reflect his commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…